Background There were two GLP-1 products that were initially approved and marketed for treating type-2 diabetes but, because they also had successful weight loss results, the manufacturers each got FDA approval to sell the products under two separate indications, one indicated for type 2 diabetes and one for weight loss, each with its own brand name and National Drug Code (NDC) identification number
PubMed, Xiao, Yunjun, et al
Semaglutide App for GLP-1 may have workflows, communities, device integrations, or content formats that some users still prefer
The efficacy of iron chelators in ALD treatment is needed to be further validated in animal studies, which would provide evidence for clinical trials
For L-arginine, estimates vary